Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Cardlytics Inc (NASDAQ: CDLX) closed at $1.04 in the last session, down -3.70% from day before closing price of $1.08. In other words, the price has decreased by -$3.70 from its previous closing price. On the day, 0.8 million shares were traded. CDLX stock price reached its highest trading level at $1.0901 during the session, while it also had its lowest trading level at $1.03.
Ratios:
We take a closer look at CDLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.14.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned the stock a target price of $4.
On August 16, 2024, Northland Capital Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $5.
BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for the stock was revised from $4 to $3.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 02 ’25 when Lynton Nicholas Hollmeyer sold 6,098 shares for $2.27 per share. The transaction valued at 13,849 led to the insider holds 116,327 shares of the business.
Gupta Amit sold 7,799 shares of CDLX for $17,712 on Oct 02 ’25. The Chief Executive Officer now owns 498,310 shares after completing the transaction at $2.27 per share. On Oct 02 ’25, another insider, DeSieno Alexis, who serves as the Chief Financial Officer of the company, sold 8,493 shares for $2.27 each. As a result, the insider received 19,288 and left with 195,417 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 56218808 and an Enterprise Value of 233690816. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.22. Its current Enterprise Value per Revenue stands at 0.93 whereas that against EBITDA is -9.407.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.08, which has changed by -0.71875 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $4.05, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -34.76%, while the 200-Day Moving Average is calculated to be -39.96%.
Shares Statistics:
According to the various share statistics, CDLX traded on average about 4.93M shares per day over the past 3-months and 787790 shares per day over the past 10 days. A total of 53.81M shares are outstanding, with a floating share count of 51.23M. Insiders hold about 5.23% of the company’s shares, while institutions hold 42.22% stake in the company. Shares short for CDLX as of 1764288000 were 5610970 with a Short Ratio of 1.14, compared to 1761868800 on 6389523. Therefore, it implies a Short% of Shares Outstanding of 5610970 and a Short% of Float of 12.0699994.
Earnings Estimates
. The current market rating for Cardlytics Inc (CDLX) reflects the collective analysis of 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.11 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.48 and -$0.59 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.31, with 3.0 analysts recommending between -$0.2 and -$0.42.
Revenue Estimates
According to 4 analysts,. The current quarter’s revenue is expected to be $55.17M. It ranges from a high estimate of $57.95M to a low estimate of $53.02M. As of. The current estimate, Cardlytics Inc’s year-ago sales were $74MFor the next quarter, 4 analysts are estimating revenue of $49.4M. There is a high estimate of $52.5M for the next quarter, whereas the lowest estimate is $47.7M.
A total of 5 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $237.39M, while the lowest revenue estimate was $230.2M, resulting in an average revenue estimate of $232.79M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $220.24M in the next fiscal year. The high estimate is $237.2M and the low estimate is $202.24M.
